Intelligent Bio Solutions Inc.

Item Amendments 5.03 to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 12, 2026, the Board of Directors of Intelligent Bio Solutions Inc. (the “Company”) adopted the Second Amended and Restated Bylaws of Intelligent Bio Solutions Inc. (as amended and restated, the “Bylaws”), effective on such date. Capitalized terms used but not defined in this Current Report on Form 8-K shall have the meanings ascribed to them in the Bylaws. The changes to the Bylaws include revising Section 2.6 in order to clarify that any matter (other than the election of directors) brought before any meeting of stockholders shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast (excluding broker non-votes) on such matter, and to establish that abstentions will also be excluded and have no impact on the vote held on such matter. The foregoing summary of the changes effectuated by the amendment and restatement of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is included as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item Regulation 7.01 FD Disclosure. Pursuant to Regulation FD, the Company hereby furnishes the presentation (the “Presentation”) that the Company made available to investors on October 13, 2026, relating to the Company’s business and operations. The Presentation can be accessed by visiting the Investors section of the Company’s website: www.ibs.inc. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.